Difference between revisions of "Team:Austin UTexas/Results"

Line 207: Line 207:
  
  
<p>Along with being one of the canonical amino acids utilized in protein synthesis, glutamate plays an important role as the main amino-group donor in the biosynthesis of nitrogen-containing compounds such as amino acids and nucleotides. Thus, we hypothesized that <i>gadB</i> overexpression via the P8 and P32 constitutive promoters and the high-copy number ColE1 origin induced a high metabolic load on the cells by shunting away glutamate from essential anabolic pathways. We believed that transformants containing the mutationally degraded <i>gadB</i> gene were selected for. In contrast, transformants containing the functional <i>gadB</i> gene were selected against due to having a depletion of glutamate substrates needed for important cellular processes. )</p>
+
<p>Along with being one of the canonical amino acids utilized in protein synthesis, glutamate plays an important role as the main amino-group donor in the biosynthesis of nitrogen-containing compounds such as amino acids and nucleotides (4, 5). Thus, we hypothesized that <i>gadB</i> overexpression via the P8 and P32 constitutive promoters and the high-copy number ColE1 origin induced a high metabolic load on the cells by shunting away glutamate from essential anabolic pathways. We believed that transformants containing the mutationally degraded <i>gadB</i> gene were selected for. In contrast, transformants containing the functional <i>gadB</i> gene were selected against due to having a depletion of glutamate substrates needed for important cellular processes. )</p>
  
 
<br>
 
<br>
Line 232: Line 232:
 
<h2 style="font-family: verdana; font-size: 35px">Creating a Golden Gate compatible vector</h2>
 
<h2 style="font-family: verdana; font-size: 35px">Creating a Golden Gate compatible vector</h2>
  
<p style="font-family: verdana">After confirming <i>gadB</i> overexpression in <i>E. coli</i>, we want to assemble our final GABA overexpression cassette plasmid using the vector pMSP3535 as the backbone (Fig. 9). To do this, we first needed to make pMSP3535 Golden Gate compatible (i.e. free of BsaI restriction sites and containing correct overhangs for cassette assembly). We chose to work with pMSP3535 as it contains both a ColE1 origin for replication in <i>E. coli</i> and a pAMb1 origin for replication in Gram-positive bacteria including <i>Lactobacillus</i> species (4). Additionally, the pMSP3535 vector contains the resistance gene for erythromycin, which <i>Lactobacillus plantarum</i> is naturally susceptible to (5)
+
<p style="font-family: verdana">After confirming <i>gadB</i> overexpression in <i>E. coli</i>, we want to assemble our final GABA overexpression cassette plasmid using the vector pMSP3535 as the backbone (Fig. 9). To do this, we first needed to make pMSP3535 Golden Gate compatible (i.e. free of BsaI restriction sites and containing correct overhangs for cassette assembly). We chose to work with pMSP3535 as it contains both a ColE1 origin for replication in <i>E. coli</i> and a pAMb1 origin for replication in Gram-positive bacteria including <i>Lactobacillus</i> species (6). Additionally, the pMSP3535 vector contains the resistance gene for erythromycin, which <i>Lactobacillus plantarum</i> is naturally susceptible to (7)
  
 
<br>
 
<br>
Line 330: Line 330:
  
  
<p style="font-family: verdana"><i> Lactobacillus plantarum </i> is a gram-positive lactic acid producing bacteria, so it requires a different growth media than we typically use in our lab. In 1954, Briggs agar was developed (5). This media was designed for lactobacilli, but was not sufficient for many species, including <i> Lactobacillus plantarum </i>, so a different non-selective media for general lactobacilli was developed in 1960 by Man, Rogosa and Sharpe and named MRS(6). We have exclusively grown our <i> Lactobacillus plantarum </i> on MRS media. Further, we grew <i> Lactobacillus plantarum </i> in a CO2 incubator as referenced in most literature we studied (1)(2)(3). The metabolic pathways in the bacteria alters when grown aerobically to produce excess acetate (7) and less lactic acid. Because we intend to utilize this bacteria in a fermentable food, a change in this metabolic pathway would not benefit our ultimate goal.</p>
+
<p style="font-family: verdana"><i> Lactobacillus plantarum </i> is a gram-positive lactic acid producing bacteria, so it requires a different growth media than we typically use in our lab. In 1954, Briggs agar was developed (8). This media was designed for lactobacilli, but was not sufficient for many species, including <i> Lactobacillus plantarum </i>, so a different non-selective media for general lactobacilli was developed in 1960 by Man, Rogosa and Sharpe and named MRS (9). We have exclusively grown our <i> Lactobacillus plantarum </i> on MRS media. Further, we grew <i> Lactobacillus plantarum </i> in a CO2 incubator as referenced in most literature we studied (10-12). The metabolic pathways in the bacteria alters when grown aerobically to produce excess acetate (13) and less lactic acid. Because we intend to utilize this bacteria in a fermentable food, a change in this metabolic pathway would not benefit our ultimate goal.</p>
  
 
<button class="accordion">MRS Media</button>
 
<button class="accordion">MRS Media</button>
Line 340: Line 340:
  
  
<p style="font-family: verdana">Once we could successfully grow our chosen bacteria, we needed to  transform the gram positive, <i> Lactobacillus plantarum</i>, with pMSP3535. In order to do this, we identified and worked with a different protocol than we had ever used in our lab. We attempted several protocols, including Landete 2014 (2) and Speer 2012 (1). However, we found success using a variation of the Welker protocol(3). Welker et al.  transformed multiple strains of <i>Lactobacillus casei</i> using varying reagents and yielded different efficiencies between each strain of the species with each variation (3).</p>  
+
<p style="font-family: verdana">Once we could successfully grow our chosen bacteria, we needed to  transform the gram positive, <i> Lactobacillus plantarum</i>, with pMSP3535. In order to do this, we identified and worked with a different protocol than we had ever used in our lab. We attempted several protocols, including Landete 2014 (14) and Speer 2012 (15). However, we found success using a variation of the Welker protocol(16). Welker et al.  transformed multiple strains of <i>Lactobacillus casei</i> using varying reagents and yielded different efficiencies between each strain of the species with each variation.</p>  
  
  
Line 399: Line 399:
  
  
<p style="font-family: verdana">The cells were washed several more times with water and 30% PEG 8000, then stored in a -80°C freezer. These cells should stay viable for up to two years.To enhance the transformation efficiency, 600 μL of prepared cells were suspended 900 μL of cold, sterile, distilled water for 30 min as a pretreatment to electroporation.The cells were pelleted and washed several times with water and 30% PEG 8000. We added 100 ng of plasmid DNA to 100μL of cell suspension as opposed to 200 ng that the protocol recommends; our first plasmid of choice was pMSP3535. This plasmid expresses erythromycin resistance. The cells were electroporated in 2mm cuvettes using the Ec3 settings on the BioRad electroporator which corresponds to 600Ω and 3 kV, differing from the Welker protocol recommendations.
+
<p style="font-family: verdana">The cells were washed several more times with water and 30% PEG 8000, then stored in a -80°C freezer. These cells should stay viable for up to two years.To enhance the transformation efficiency, 600 μL of prepared cells were suspended 900 μL of cold, sterile, distilled water for 30 min as a pretreatment to electroporation.The cells were pelleted and washed several times with water and 30% PEG 8000. We added 100 ng of plasmid DNA to 100μL of cell suspension as opposed to 200 ng that the protocol recommends; our first plasmid of choice was pMSP3535. This plasmid expresses erythromycin resistance. The cells were electroporated in 2mm cuvettes using the Ec3 settings on the BioRad electroporator which corresponds to 600Ω and 3 kV, differing from the Welker protocol recommendations.
 
After cells were electroporated, they recovered overnight in the appropriate recovery media. They were plated on MRS agar plates with 10μg/mL erythromycin and left to grow for 2 days. </p>
 
After cells were electroporated, they recovered overnight in the appropriate recovery media. They were plated on MRS agar plates with 10μg/mL erythromycin and left to grow for 2 days. </p>
  

Revision as of 03:30, 1 November 2017

div class = "column full_size_outer" id = "top">

Click on one of the images below to learn more about our results!



Golden Gate Assembly

Although bacteria can naturally synthesize GABA, we wanted to increase expression of the gadB gene and subsequently GABA production in order to imbue our probiotic with a more potent medicinal quality, with the idea that this GABA-overproducing probiotic can then be consumed by patients with bowel disorders or anxiety (1). Overexpression of the gadB gene will be accomplished by placing it under the control of either the P8 or P32 constitutive promoters from Lactococcus lactis (2). To make our GABA-producing probiotic we first needed to assemble a GABA overexpression cassette plasmid using the Golden Gate assembly method. The intention here is that bacteria containing this GABA overexpression cassette plasmid should produce high levels of GABA. In short, Golden Gate Assembly is a new cloning method that allows for the creation of a multi-part DNA assembly (i.e. cassette plasmid) in a single reaction through the use of DNA parts containing specific, predefined suffixes and prefixes with recognition sites for Type IIs restriction enzymes (e.g. BsmBI and BsaI). The specificity of these suffixes and prefixes provides directionality of the desired DNA parts during the assembly process. For our purposes, we used the MoClo Yeast Tool Kit developed by John Dueber (3).

Creating a Golden Gate compatible vector

After confirming gadB overexpression in E. coli, we want to assemble our final GABA overexpression cassette plasmid using the vector pMSP3535 as the backbone (Fig. 9). To do this, we first needed to make pMSP3535 Golden Gate compatible (i.e. free of BsaI restriction sites and containing correct overhangs for cassette assembly). We chose to work with pMSP3535 as it contains both a ColE1 origin for replication in E. coli and a pAMb1 origin for replication in Gram-positive bacteria including Lactobacillus species (6). Additionally, the pMSP3535 vector contains the resistance gene for erythromycin, which Lactobacillus plantarum is naturally susceptible to (7)

Figure 9. Golden Gate assembly of the GABA final overexpression cassette plasmid with the Golden Gate compatible pMSP3535 vector and the P8/P32 promoter, gadB gene, and M13 terminator part plasmids.



The process of making the pMSP3535 vector Golden Gate compatible involved two steps: 1) assembling the pMSP3535 backbone (pAMb1 origin and erythromycin resistance gene) with a new ColE1 origin; 2) assembling a gfp dropout part to the assembly of the pMSP3535 backbone and the new ColE1 origin (Fig. 10).



Figure 10. Assembly workflow for creating the Golden Gate compatible pMSP3535 backbone. The first step involves replacing the ColE1 origin in the pMSP3535 backbone with a new ColE1 origin from pYTK001 to create a pMSP3535 + ColE1 assembly. The second step involves combining the pMSP3535 + ColE1 assembly with a gfp dropout to form the final Golden Gate compatible vector to be used to create our GABA overexpression plasmid.



Since the original pMSP3535 vector contained two illegal BsaI sites within the ColE1 origin, we sought to replace this ColE1 origin with a BsaI-free one isolated from pYTK001. This assembly process involved linearizing and adding BsmBI sites and compatible overhangs to the pMSP3535 backbone and the pYTK001 ColE1 origin via PCR. After the pMSP3535 backbone and ColE1 origin were successfully amplified by PCR (Fig. 11a), they were joined together using BsmBI assembly. Diagnostic PCR was performed on pMSP3535 + ColE1 minipreps from E. coli transformants to screen for positive samples containing both the pMSP3535 backbone and the ColE1 inserts (Fig. 11b). After confirming the presence of the pMSP3535 vector and ColE1 origin, we partially sequence-confirmed the two miniprep samples.



Figure 11. (A) Agarose gel of successful PCR for the pMSP3535 backbone and the ColE1 origin. Lane 1 contains a negative PCR control. Lanes 2 and 3 contain the ColE1 origin (around 800 bp) and pMSP3535 backbone PCR products (around 4.3 kb). (B) Agarose gel of diagnostic PCR of miniprep samples from pMSP3535 + ColE1 transformants. Lane 1 contains a negative PCR control. Lane 2 contains a positive PCR control for the pMSP3535 backbone, while lanes 3 and 4 contain the pMSP3535 PCR from two miniprep samples. Lane 7 contains a positive PCR control for the ColE1 origin, while lanes 8 and 9 contain the ColE1 PCR from the same two miniprep samples. Evidently, the pMSP3535 backbone and ColE1 origin is present in both tested miniprep samples.



To this pMSP3535 + ColE1 assembly, we wanted to add a gfp dropout part containing internal BsaI sites that will generate overhangs compatible with those in the P8/P32 promoter and M13 terminator part plasmids. Additionally, the incorporation of this gfp dropout part will also allow us to visually screen for positive and negative transformants based on their fluorescence. BsmBI sites and compatible overhangs were added to the gfp dropout part by PCR amplifying it from pYTK047 (Fig. 12). We have been attempting to linearize and add BsmBI sites and overhangs to the positive pMSP3535 + ColE1 assemblies via PCR, with no success. However, results from diagnostic digests suggested that our assemblies may have contained extra, undesired DNA such as IS elements (Fig. 13). Thus, as of right now, we are screening for more positive pMSP3535 + ColE1 transformants. Once we have trouble-shooted this problem, the pMSP3535 + ColE1 and the gfp dropout PCR products will be joined through BsmBI assembly to form the final Golden Gate compatible pMSP3535 vector.

Figure 12. Agarose gel of gfp dropout PCR from pYTK047. Lane 1 contains a negative PCR control. Lane 2 contains the gfp dropout PCR product with an expected band length of around 1 kb.



Figure 13. Agarose gel of pMSP3535 + ColE1 assembly diagnostic digests. Lane 1 contains the undigested plasmid assembly. Lane 2 contains the ClaI-digested plasmid with expected 400 bp and 4.6 kb bands. The actual band generated is apparently above 10 kb. Lane 3 contains the XmnI-digested plasmid with expected 200 bp, 1.5 kb, and 3.3 kb bands. The generated band sizes were 2.5 kb and 4 kb. Lane 4 contains the KpnI-digested assembly with an expected 5.1 kb band. The generated band size was 6 kb. Lane 5 contains the Bg1II-digested assembly with an expected 5.1 kb band. The generated band size was 8 kb.



Assessing erythromycin susceptibility of E. coli



Since we are creating our Golden Gate compatible pMSP3535 shuttle vector in E. coli, we wanted to determine the natural susceptibility of E. coli to erythromycin as the minimum concentration to use has not been established clearly in the literature. Thus, we performed an erythromycin minimum inhibitory concentration test in liquid LB media (Fig. 14). After one-day incubation, we observed that E. coli was resistant up to around 150 µg/mL of erythromycin. From this experiment, we have determined that the optimal erythromycin concentration for selecting against E. coli in liquid culture is around 200-250 µg/mL.



Figure 14. Erythromycin minimum inhibitory concentration tests for E. coli in liquid media. From left to right: 0 µg/mL, 50 µg/mL, 100 µg/mL, 150 µg/mL, 200 µg/mL, 250 µg/mL, 300 µg/mL, 350 µg/mL, and 400 µg/mL.


References

  1. Yunes, R. A et al. GABA production and structure of gadB/gadC genes in Lactobacillus and Bifidobacterium strains from human microbiota. Anaerobe. 42: 197-204 (2016).
  2. Zhu, D. et al. Isolation of strong constitutive promoters from Lactococcus lactis subsp. Lactis N8. FEMS Microbiol Lett. 363(16): pii: fnv107 (2015).
  3. Lee, M. E. et al. A Highly Characterized Yeast Toolkit for Modular, Multipart Assembly. ACS Synth. Biol. 4(9): 975-86 (2015).
  4. Pérez-Arellano, I. et al. Construction of Compatible Wide-Host-Range Shuttle Vectors for Lactic Acid Bacteria and Escherichia coli. Plasmid. 46(2): 106-16 (2001).
  5. Flórez A. B. et al. Susceptibility of Lactobacillus plantarum Strains to Six Antibiotics and Definition of New Susceptibility–Resistance Cutoff Values. Microbial Drug Resistance. 12(4): 252-56 (2007).